ALCON INC business relationships
Companies named in ALCON INC’s 20-F filed 2026-02-24, and public companies whose annual reports name ALCON INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.6 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in ALCON INC’s annual report 1
“On May 22, 2023, Alcon entered into financing arrangements with a long-term supplier, Lifecore Biomedical, Inc. and certain of its affiliates (collectively, "Lifecore").” SEC filing
Companies whose annual reports name ALCON INC 7
“License Agreement by and among Alcon Research, LTD., and Oculis, dated December 19, 2018” SEC filing
“Other than EYSUVIS and INVELTYS, which we sold to Alcon in July 2022, we have not received approval to market any product candidate from regulatory authorities in any jurisdiction.” SEC filing
“Alcon and the other customer accounted for 42% and 16%, respectively, of our revenue during the transition period ended December 31, 2025.” SEC filing
“The Alcon Supply Agreement includes annual committed capacity obligations on the Company without minimum purchase obligations on Alcon, and the Alcon CMA also includes annual committed capacity obligations on the Company, and both agreements permit Alcon to source from other third parties.” SEC filing
“Novartis, Zuelling and Alcon - accounted for approximately 53.7% of the company's total revenue for the year ended December” SEC filing
“global pharmaceutical companies such as Novartis and Alcon, as well as having licensing partnerships with EG BioMed for pancreatic and” SEC filing
“Alcon, as a supplier of clinical testing drugs.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.